Our research over the past decade has compellingly demonstrated the potential of Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor agonists in Alzheimer’s disease (AD) treatment. Here, NOD2 is linked to early-onset autosomal dominant Alzheimer disease.